Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lupus nephritis: treatment issues.

H M Belmont1

  • 1Hospital for Joint Diseases, New York University Medical Center, New York, New York 10003, USA. hmb1@is2.nyu.edu

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resolution of large aortic valve vegetations in antiphospholipid syndrome treated with therapeutic anticoagulation: a report of two cases and literature review.

Lupus·2018
Same author

Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.

BJOG : an international journal of obstetrics and gynaecology·2018
Same author

Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.

Lupus·2017
Same author

Disseminated cytomegalovirus infection complicating active treatment of systemic lupus erythematosus: an emerging problem.

Lupus·2016
Same author

When rectal bleeding is serious: anal squamous cell carcinoma in two intravenous cyclophosphamide treated systemic lupus erythematosus patients with human papilloma virus infection.

Lupus·2013
Same author

Pseudo-pseudo Meigs' syndrome in a patient with systemic lupus erythematosus.

Lupus·2012
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Effective lupus nephritis treatment involves understanding disease types and using therapies like glucocorticoids and cyclophosphamide. While current treatments preserve kidney function, novel agents are needed for better efficacy and reduced toxicity.

Area of Science:

  • Nephrology
  • Immunology
  • Internal Medicine

Background:

  • Lupus nephritis treatment requires understanding pathogenesis and risk stratification.
  • Different lupus nephritis variants (mesangial, proliferative, membranous) have varying prognoses.
  • Active lupus nephritis necessitates prompt immunomodulatory therapy.

Purpose of the Study:

  • To review current therapeutic options for lupus nephritis.
  • To discuss the role of glucocorticoids and cyclophosphamide.
  • To highlight the need for novel, more effective, and less toxic agents.

Main Methods:

  • Review of existing literature on lupus nephritis treatment.
  • Classification of lupus nephritis based on World Health Organization (WHO) criteria.

Related Experiment Videos

  • Analysis of therapeutic strategies including glucocorticoids, cyclophosphamide, and ancillary management.

    • Main Results:

    • Glucocorticoids (prednisone, methylprednisolone) are primary treatments for active lupus nephritis.
    • Cyclophosphamide serves as effective salvage therapy for glucocorticoid non-responders.
    • Ancillary management includes hypertension control, ACE inhibitors, and dietary modifications.

    Conclusions:

    • Current lupus nephritis treatments preserve renal function in most patients.
    • Glucocorticoids and cyclophosphamide are established therapies.
    • Development of novel agents with improved efficacy and safety profiles is crucial.